Loading…
← CockpitCompetitor Analysis › 603235.SS JiangXi Tianxin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

JiangXi Tianxin Pharmaceutical Co., Ltd. Class A603235.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Jiangxi-based pharmaceutical manufacturer selling generic and traditional-medicine drugs in China.

Momentum leader 81
Mkt cap
$1.52B
US dollars, full cap
Free float
34%
of shares outstanding
$/day
$1.85M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+10.2 pp
WACC 5.1%
Hurdle
-5 pp
Req g minus delivered
Close · CNYCN¥23.27
1D-1.1%
1W-4.7%
1M-9.0%
3M-1.6%
6M-9.1%
YTD-13.7%
1Y-14.1%
ATR %2.4%
52w lowhigh19.1% off high

What JiangXi Tianxin Pharmaceutical does

Jiangxi-based pharmaceutical manufacturer selling generic and traditional-medicine drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics and TCM

Moat: none

Headquarters: Jiangxi, China · Employees: 2,893

JiangXi Tianxin Pharmaceutical at a glance

Size JiangXi Tianxin Pharmaceutical (603235.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.52B, the 1503rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.27 on 18 Nov 2026.

Performance Over six months the shares fell 9.1%, against -11.1% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 16.3% over the last twelve months (peer median +4.1%); the operating margin is 24.4% (peer median 9.9%).

Valuation It trades at 3.5× enterprise value to sales against a peer median of 4.5× (9th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.2 points above its cost of capital (5.1% WACC).

Relative performance

909510021 May 202621 Aug 202618 Nov 2026603235.SS 92Peer median 90
Six months, rebased to 100: JiangXi Tianxin Pharmaceutical against the median of its 20 peers (local-currency closes).

JiangXi Tianxin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.58BCN¥2.33BCN¥2.20BCN¥1.87BCN¥2.29B
Revenue growth—+6%+17%-18%—
Gross profitCN¥1.19BCN¥947MCN¥891MCN¥689MCN¥833M
EBITDAn/aCN¥825MCN¥774MCN¥550MCN¥701M
Net incomeCN¥552MCN¥592MCN¥651MCN¥476MCN¥622M
Free cash flowCN¥381MCN¥48.7M-CN¥567MCN¥194MCN¥346M
Capital expenditureCN¥326MCN¥581MCN¥1.07BCN¥536MCN¥260M
Total debtCN¥549MCN¥445MCN¥204MCN¥170MCN¥68.1M

Quarterly statements and history in the cockpit →

JiangXi Tianxin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%600572298380141080CORONASRPT002019002626002675JUBLPHARMAPAHC600420002755301047140410ANURAS310210MARKSANS4516DMRAASTRAZEN603235.SS6-month return →1-month return →
Up and to the right = strong over both horizons. JiangXi Tianxin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-100%-50%0%0×25,000×50,000×75,000×600572298380141080CORONASRPT002019JUBLPHARMA310210603235.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JiangXi Tianxin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%600572CORONASRPT002675PAHC600420002755301047MARKSANS4516ASTRAZEN603235.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. JiangXi Tianxin Pharmaceutical is the large dot.

JiangXi Tianxin Pharmaceutical competitors and peer comparison

How JiangXi Tianxin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JiangXi Tianxin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603235.SSPeer medianRank in peer set
1-month return-9.0%-3.8%7th lowest of 21
6-month return-9.1%-11.1%11th highest of 21
Distance from 52-week high-19.1%-40.1%4th highest of 21
Revenue growth (TTM)+16.3%+4.1%8th highest of 20
Operating margin24.4%9.9%highest of 20
EV / Sales3.5×4.5×9th cheapest of 20
Growth the price implies (Req g, 7 yrs)-4.9%6.0%6th least demanding of 12
Growth delivered (Del g)+0.2%+7.0%5th lowest of 12
Hurdle (Req g minus delivered)-5.1 pp+10.3 pp5th least demanding of 12
ROIC minus cost of capital+10.2 pp-1.3 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%3.5×-4.9%+0.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%46.5×n/an/a
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%17.0×n/an/a
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%8.9×36.3%+16.6%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%0.9×-6.8%+32.4%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%2.5×n/an/a
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%3.1×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%4.5×6.0%-4.3%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%2.0×n/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%1.2×-6.6%-5.6%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%5.2×12.8%-14.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%9.8×31.1%-15.1%
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%7.2×n/an/a
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%5.6×42.4%+23.0%

Questions

Which companies are JiangXi Tianxin Pharmaceutical's closest peers?
The cockpit's peer set: Zhejiang CONBA Pharmaceutical (600572.SS), ABL Bio (298380.KS), LigaChem Biosciences (141080.KS), Corona Remedies (CORONA.NS), Sarepta Therapeutics (SRPT), Yifan Pharmaceutical (002019.SZ), Xiamen Kingdomway (002626.SZ), Yantai Dongcheng Biochemicals (002675.SZ).
Is JiangXi Tianxin Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.5× against a peer median of 4.5×, 9th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has JiangXi Tianxin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -9.1% against -11.1% for the median peer; over one year -14.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.